Titan Investment Management LLC Buys New Position in IDEXX Laboratories, Inc. $IDXX

Titan Investment Management LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,476 shares of the company’s stock, valued at approximately $1,675,000. IDEXX Laboratories makes up approximately 1.5% of Titan Investment Management LLC’s portfolio, making the stock its 26th largest position.

A number of other large investors have also recently added to or reduced their stakes in the stock. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories in the fourth quarter worth approximately $3,666,459,000. J. Stern & Co. LLP lifted its position in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after acquiring an additional 2,642,200 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of IDEXX Laboratories by 318.1% during the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after acquiring an additional 592,834 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth $332,265,000. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group cut their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $562.09 on Friday. The firm has a market cap of $44.34 billion, a P/E ratio of 41.39, a price-to-earnings-growth ratio of 2.99 and a beta of 1.55. The firm’s 50-day simple moving average is $562.26 and its 200-day simple moving average is $621.32. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm posted $2.91 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.